What question did this study set out to answer?

To evaluate the neutrophil CD64 index as a biomarker for severity prediction in hemorrhagic fever with renal syndrome (HFRS).

April 8, 2026Open Access

Clinical Value the Neutrophil CD64 Index in Predicting the Severity of Hemorrhagic Fever With Renal Syndrome

To evaluate the neutrophil CD64 index as a biomarker for severity prediction in hemorrhagic fever with renal syndrome (HFRS).
Analyzed neutrophil CD64 levels in patients with HFRS
Monitored disease progression over time
Assessed treatment efficacy using biomarker levels
Higher neutrophil CD64 index correlates with increased disease severity
The index can effectively monitor disease progression
Potential to guide treatment decisions based on biomarker changes

The nCD64 index has the potential to serve as an effective biomarker for monitoring disease progression and assessing treatment efficacy in HFRS.

KI fragen

Bookmark

View Full Paper

Ye et al. (Wed,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper